Journal of International Oncology››2018,Vol. 45››Issue (1): 59-.doi:10.3760/cma.j.issn.1673-422X.2018.01.014
Previous ArticlesNext Articles
Wang Yanjun, Kang Xiaojing
Online:
2018-01-08Published:
2018-02-12Contact:
Kang Xiaojing E-mail:drkangxj666@163.comSupported by:
Wang Yanjun, Kang Xiaojing. Biomarkers for malignant melanoma[J]. Journal of International Oncology, 2018, 45(1): 59-.
[1] Sari Aslani F, Geramizadeh B, Dehghanian AR. Comparison of cKit expression between primary and metastatic melanoma of skin and mucosa[J]. Med J Islam Republic Iran, 2015, 29: 203. [2] Walesch SK, Richter AM, Helmbold P, et al. Claudin11 promoter hypermethylation is frequent in malignant melanoma of the skin, but uncommon in nevus cell nevi[J]. Cancers (Basel), 2015, 7(3): 12331243. DOI: 10.3390/cancers7030834. [3] Bruno W, Martinuzzi C, Andreotti V, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry[J]. Oncotarget, 2017, 8(5): 80698082. DOI: 10.18632/oncotarget.14094. [4] Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma[J]. J Mol Diagn, 2013, 15(2): 220226. DOI: 10.1016/j.jmoldx.2012.10.002. [5] Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib[J]. N Engl J Med, 2015, 372(1): 3039. DOI: 10.1056/NEJMoa1412690. [6] Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAFmutated melanoma[J]. N Engl J Med, 2014, 371(20): 18671876. DOI: 10.1056/NEJMoa1408868. [7] Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a nonrandomised, openlabel phase 2 study[J]. Lancet Oncol, 2013, 14(3): 249256. DOI: 10.1016/S14702045(13)70024X. [8] Slipicevic A, Herlyn M. KIT in melanoma: many shades of gray[J]. J Invest Dermatol, 2015, 135(2): 337338. DOI: 10.1038/jid.2014.417. [9] Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sunexposed melanomas[J]. Nat Genet, 2015, 47(9): 9961002. DOI: 10.1038/ng.3361. [10] Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma[J]. Melanoma Res, 2014, 24(6): 525534. DOI: 10.1097/CMR.0000000000000121. [11] Ji ZY, Njauw CN, Taylor M, et al. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition[J]. J Invest Dermatol, 2012, 132(2): 356364. DOI: 10.1038/jid.2011.313. [12] Mazar J, Deblasio D, Govindarajan SS, et al. Epigenetic regulation of microRNA375 and its role in melanoma development in humans[J]. FEBS Lett, 2011, 585(15): 24672476. DOI: 10.1016/j.febslet.2011.06.025. [13] Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma[J]. J Transl Med, 2012, 10(1): 155161. DOI: 10.1186/1479587610155. [14] Segura MF, Greenwald HS, Hanniford D, et al. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy[J]. Carcinogenesis, 2012, 33(10): 18231832. DOI: 10.1093/carcin/bgs205. [15] Shiiyama R, Fukushima S, Jinnin MA, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles[J]. Melanoma Res, 2013, 23(5): 366372. DOI: 10.1097/CMR.0b013e328363e485. [16] Tian R, Liu T, Qiao L, et al. Decreased serum microRNA206 level predicts unfavorable prognosis in patients with melanoma[J]. Int J Clin Exp Pathol, 2015, 8(3): 30973103. [17] Kostaki M, Manona AD, Stavraka I, et al. Highfrequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1expression in sporadic cutaneous melanoma[J]. Exp Dermatol, 2014, 23(5): 332338. DOI: 10.1111/exd.12398. [18] Lauss M, Ringner M, Karlsson A, et al. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes[J]. BMC Med Genomics, 2015, 8: 73. DOI: 10.1186/s1292001501474. [19] Otsubo T, Hagiwara T, TamuraNakano M, et al. Aberrant DNA hypermethylation reduces the expression of the desmosomerelated molecule periplakin in esophageal squamous cell carcinoma[J]. Cancer Med, 2015, 4(3): 415425. DOI: 10.1002/cam4.369. [20] Micevic G, Theodosakis N, Taube JM, et al. Attenuation of genomewide 5methylcytosine level is an epigenetic feature of cutaneous malignantmelanomas[J]. Melanoma Res, 2017, 27(2): 8596. DOI: 10.1097/CMR.0000000000000315. [21] PerezRamirez C, CanadasGarre M, Angel Molina M, et al. PTEN and PI3K/AKT in nonsmallcell lung cancer[J]. Pharmacogenomics, 2015, 16(16): 18431862. DOI: 10.2217/pgs.15.122. [22] Roh MR, Gupta S, Park KH, et al. Promoter methylation of PTEN is a significant prognostic factor in melanoma survival[J]. J Invest Dermatol, 2016, 136(5): 10021011. DOI: 10.1016/j.jid.2016.01.024. [23] Hoshimoto S, Kuo CT, Chong KK, et al. AIM1 and LINE1 epigenetic aberrations in tumor and serum Relate to melanoma progression and disease outcome[J]. J Invest Dermatol, 2012, 132(6): 16891697. DOI: 10.1038/jid.2012.36. |
[1] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[2] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[3] | Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili.RNF43 inhibits PD-L1 expressionviaβ-catenin in melanoma cells and promotes CD8+T cell-mediated anti-tumor immune reaction[J]. Journal of International Oncology, 2023, 50(7): 407-412. |
[4] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[5] | Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing.Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy[J]. Journal of International Oncology, 2023, 50(10): 600-607. |
[6] | He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang.Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563. |
[7] | Hu Ru, Li Donglin, Yan Xuebing.Methyltransferase like protein 14 and tumor[J]. Journal of International Oncology, 2022, 49(8): 478-483. |
[8] | Hong Anlan, Cao Meng, Wang Yan, Fang Fang.Research progress on lncRNAs as members of ceRNA network in melanoma[J]. Journal of International Oncology, 2022, 49(1): 61-64. |
[9] | Hu Guangyue, Yin Hong, Zhang Hui, Luo Hong.Efficacy predictors of immune checkpoint inhibitors in the treatment of metastatic gastric cancer[J]. Journal of International Oncology, 2021, 48(8): 498-501. |
[10] | Zhuang Weitao, Qiao Guibin.Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors[J]. Journal of International Oncology, 2021, 48(6): 358-361. |
[11] | Wang Hui, Xia Rong, Wei Qingwen, Wan Yixin.Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer[J]. Journal of International Oncology, 2021, 48(5): 296-301. |
[12] | Li Suyao, Huang Junxing.Research progress of biomarkers for predicting the efficacy of immunotherapy for tumor[J]. Journal of International Oncology, 2021, 48(4): 220-224. |
[13] | Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245. |
[14] | Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan.Advances in the amplification of HER2 in metastatic colorectal cancer[J]. Journal of International Oncology, 2021, 48(4): 246-249. |
[15] | Ning Dawei, Ou Yang, Cui Kai, Li Sheng, Gao Dehai.Enrichment methods and clinical application of circulating tumor cells[J]. Journal of International Oncology, 2021, 48(3): 167-171. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||